Evidence map›Paper›PMID 40133516›Full record

ArticleScientific reports2025

Coding and regulatory somatic profiling of triple-negative breast cancer in Sub-Saharan African patients.

Ricardo J Pinto, Dylan Ferreira, Paulo Salamanca, Fernando Miguel, Pamela Borges, Carla Barbosa, Vitor Costa, Carlos Lopes, Lúcio Lara Santos, Luisa Pereira

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ricardo J Pintoi3S, Instituto de Investigação e Inovação Em Saúde, Universidade do Porto, Porto, Portugal.
Dylan FerreiraResearch Center of IPO-Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.CCC) Raquel Seruca, Porto, Portugal.
Paulo SalamancaAngolan Institute Against Cancer, Luanda, Angola.
Fernando MiguelAngolan Institute Against Cancer, Luanda, Angola.
Pamela BorgesHospital Universitário Agostinho Neto, Praia, Cabo Verde.
Carla BarbosaHospital Universitário Agostinho Neto, Praia, Cabo Verde.
Vitor CostaHospital Universitário Agostinho Neto, Praia, Cabo Verde.
Carlos LopesUnilabs | Laboratório Anatomia Patológica, Porto, Portugal.
Lúcio Lara SantosResearch Center of IPO-Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.CCC) Raquel Seruca, Porto, Portugal.
Luisa Pereirai3S, Instituto de Investigação e Inovação Em Saúde, Universidade do Porto, Porto, Portugal. luisap@i3s.up.pt.

Funding

Fundação para a Ciência e a Tecnologia 2020.09384.BDFundação para a Ciência e a Tecnologia PTDC/BIA-MOL/3986/2021Fundação para a Ciência e a Tecnologia SFRH/BD/145217/2019Liga Portuguesa Contra o Cancro - Núcleo Regional do Norte Bolsas LPCC-NRN 2024
6 · The paper itself

Abstract

The burden of triple-negative breast cancer (TNBC) may be shaped by genetic factors, particularly inherited and somatic mutation profiles. However, data on this topic remain limited, especially for the African continent, where a higher TNBC incidence is observed. In the age of precision medicine, cataloguing TNBC diversity in African patients becomes imperative. We performed whole exome sequencing, including untranslated regions, on 30 samples from Angola and Cape Verde, which allowed to ascertain on potential regulatory mutations in TNBC for the first time. A high somatic burden was observed for the African cohort, with 86% of variants being so far unreported. Recurring to predictive functional algorithms, 17% of the somatic single nucleotide variants were predicted to be deleterious at the protein level, and 20% overlapped with candidate cis-regulatory elements controlling gene expression. Several of these somatic functionally-impactful mutations and copy number variation (mainly in 1q, 8q, 6 and 10p) occur in known BC- and all cancer-driver genes, enriched for several cancer mechanisms, including response to radiation and related DNA repair mechanisms. TP53 is the top of these known BC-driver genes, but our results identified possible novel TNBC driver genes that may play a main role in the African context, as TTN, CEACAM7, DEFB132, COPZ2 and GAS1. These findings emphasize the need to expand cancer omics screenings across the African continent, the region of the globe with highest genomic diversity, accelerating the discovery of new somatic mutations and cancer-related pathways.

Indexed as

Triple Negative Breast NeoplasmsAfrica South of the SaharaDNA Copy Number VariationsExome SequencingFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedMutationPolymorphism, Single NucleotideCoding and regulatory somatic profileExome and UTRs sequencingSub-Saharan African ancestryTriple-negative breast cancer

Identifiers

PMID40133516
PMCPMC11937512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.